- Home
- DMAC vs MPAA Comparison
DMAC vs MPAA Comparison
Compare DMAC & MPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- MPAA
- Stock Information
- Founded
- DMAC 2000
- MPAA 1968
- Country
- DMAC United States
- MPAA United States
- Employees
- DMAC N/A
- MPAA N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- MPAA Auto Parts:O.E.M.
- Sector
- DMAC Health Care
- MPAA Consumer Discretionary
- Exchange
- DMAC Nasdaq
- MPAA Nasdaq
- Market Cap
- DMAC 310.1M
- MPAA 327.4M
- IPO Year
- DMAC N/A
- MPAA 1994
- Fundamental
- Price
- DMAC $7.06
- MPAA $17.06
- Analyst Decision
- DMAC Strong Buy
- MPAA
- Analyst Count
- DMAC 3
- MPAA 0
- Target Price
- DMAC $12.33
- MPAA N/A
- AVG Volume (30 Days)
- DMAC 262.5K
- MPAA 116.2K
- Earning Date
- DMAC 11-12-2025
- MPAA 11-10-2025
- Dividend Yield
- DMAC N/A
- MPAA N/A
- EPS Growth
- DMAC N/A
- MPAA N/A
- EPS
- DMAC N/A
- MPAA 0.08
- Revenue
- DMAC N/A
- MPAA $775,831,000.00
- Revenue This Year
- DMAC N/A
- MPAA $10.44
- Revenue Next Year
- DMAC N/A
- MPAA $4.88
- P/E Ratio
- DMAC N/A
- MPAA $210.58
- Revenue Growth
- DMAC N/A
- MPAA 6.59
- 52 Week Low
- DMAC $3.19
- MPAA $5.16
- 52 Week High
- DMAC $7.49
- MPAA $17.72
- Technical
- Relative Strength Index (RSI)
- DMAC 57.38
- MPAA 59.70
- Support Level
- DMAC $6.64
- MPAA $16.39
- Resistance Level
- DMAC $7.13
- MPAA $17.54
- Average True Range (ATR)
- DMAC 0.27
- MPAA 0.66
- MACD
- DMAC -0.00
- MPAA 0.07
- Stochastic Oscillator
- DMAC 77.21
- MPAA 79.27
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About MPAA Motorcar Parts of America Inc.
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard part in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.